医学临床研究
  2025年4月6日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (5): 659-663    DOI: 10.3969/j.issn.1671-7171.2023.05.006
  论著 本期目录 | 过刊浏览 | 高级检索 |
H2FPEF评分、NT-proBNP联合LVDF在射血分数保留的2型糖尿病患者DCM危险程度中的评估价值
刘雪婷, 邓建新, 李海燕, 郝明瑜, 欧慧婷, 阎德文**
深圳市第二人民医院内分泌科,深圳市代谢性疾病临床医学研究中心,广东 深圳 518035
Evaluation Value of H2FPEF Score, NT-proBNP and LVDF in the Risk of DCM in Type 2 Diabetes Patients with Ejection Fraction Preserved
LIU Xue-ting, DENG Jian-xin, LI Hai-yan, et al
Department of Endocrinology, Shenzhen Second People's Hospital/Shenzhen Clinical Research Center for Metabolic Disease, Shenzhen Guangdong 518035
全文: PDF (1227 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨H2FPEF评分、N端B型利钠肽前体(NT-proBNP)联合左心室舒张功能(LVDF)在射血分数(EF)保留的2型糖尿病(T2DM)患者糖尿病心肌病(DCM)危险程度中的评估价值。【方法】回顾性分析2014年2月至2019年4月在深圳市第二人民医院诊治的593例EF≥50%的T2DM患者的临床资料。以H2FPEF评分、NT-proBNP和LVDF为关键指标,首先采用聚类分析方法对研究人群进行DCM危险程度分类,获得DCM危险分期;然后对上述分期进行Fisher判别分析,获得DCM危险分期的判断方法。【结果】通过聚类分析将研究对象分为DCM危险4期:1期为DCM低危期,有98例(16.52%),其H2FPEF低评分为(0.52±0.50)分,NT-proBNP为(38.98±24.80)pg/mL,LVDF正常;2期为DCM中危期,有469例(79.09%),其H2FPEF低评分为(1.47±0.92)分,NT-proBNP正常[(61.79±54.22)pg/mL],LVDF降低;3期为DCM高危期,有17例(2.87%),其H2FPEF低评分为(1.53±1.18)分,NT-proBNP升高[(344.18±106.94)pg/mL],LVDF降低;4期为极高危期,有9例(1.52%),其中H2FPEF评分为(2.89±1.17)分、NT-proBNP升高[(550.44±153.87)pg/mL],LVDF降低。对上述4期进行Fisher判别分析获得4个贝叶斯判别函数,准确率均大于90%,该判别函数可对EF≥50%的T2DM患者进行DCM危险分期的判断。【结论】H2FPEF评分、NT-proBNP联合LVDF为评价EF保留的T2DM患者DCM危险程度提供了一种新判断方法。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 糖尿病, 2型心肌病, 扩张型利钠肽,脑/血液心排血量    
Abstract:【Objective】 To investigate the effects of H2FPEF score, N-terminal B-type natriuretic peptide precursor (NT-proBNP) combined with left ventricular diastolic function (LVDF) on the evaluation value of risk degree of diabetes cardiomyopathy (DCM) in patients with type 2 diabetes (T2DM) with ejection fraction (EF) preserved. 【Methods】 A retrospective analysis was conducted on the clinical data of 593 T2DM patients with EF ≥ 50% who were treated at the Shenzhen Second People's Hospital from February 2014 to April 2019. Using H2FPEF score, NT-proBNP and LVDF as key indicators ,the cluster analysis was first used to classify the DCM risk level of the study population and obtain the DCM risk staging; Then Fisher discriminant analysis on the above stages was perform to obtain a method for determining the risk stage of DCM. 【Results】Through cluster analysis, the study subjects were divided into four phases of DCM risk: the Phase 1 was a low-risk stage of DCM, with 98 cases (16.52%) having a low H2FPEF score of (0.52 ± 0.50), an NT-proBNP score of (38.98 ± 24.80) pg/mL, and a normal LVDF; the Phase 2 was a moderate risk stage for DCM, with 469 cases (79.09%) having a low H2FPEF score of (1.47 ± 0.92), normal NT-proBNP [(61.79 ± 54.22) pg/mL], and reduced LVDF; the Phase 3 was a high-risk period for DCM, with 17 cases (2.87%) having a low H2FPEF score of (1.53 ± 1.18), an increase in NT-proBNP[(344.18 ± 106.94) pg/mL], and a decrease in LVDF; the Phase 4 was a very high-risk period, with 9 cases (1.52%), with an H2FPEF score of (2.89 ± 1.17), an increase in NT-proBNP [(550.44±153.87) pg/mL] and a decrease in LVDF. Four Bayesian discriminant functions were obtained through Fisher discriminant analysis on the above four periods, with accuracy rates greater than 90%. This discriminant function could be used to determine the DCM risk staging for T2DM patients with EF ≥ 50%. 【Conclusions】The H2FPEF score, NT-proBNP combined with LVDF provide a new method for evaluating the risk of DCM in T2DM patients with EF preservation.
Key wordsDiabetes Mellitus, Type 2    Cardiomyopathy, Dilated    Natriuretic Peptide, Brain/BL    Cardiac Output
收稿日期: 2022-10-06     
中图分类号:  R587.23  
基金资助:国家自然科学基金面上项目(项目批准号:81670759)
通讯作者: **E-mail:yandw963@126.com   
引用本文:   
刘雪婷, 邓建新, 李海燕, 郝明瑜, 欧慧婷, 阎德文. H2FPEF评分、NT-proBNP联合LVDF在射血分数保留的2型糖尿病患者DCM危险程度中的评估价值[J]. 医学临床研究, 2023, 40(5): 659-663.
LIU Xue-ting, DENG Jian-xin, LI Hai-yan, et al. Evaluation Value of H2FPEF Score, NT-proBNP and LVDF in the Risk of DCM in Type 2 Diabetes Patients with Ejection Fraction Preserved. JOURNAL OF CLINICAL RESEARCH, 2023, 40(5): 659-663.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.05.006     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I5/659
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn